Success Metrics

Clinical Success Rate

93.3%

Based on 28 completed trials

Completion Rate

93%(28/30)

Active Trials

9(20%)

Results Posted

89%(25 trials)

Terminated

2(5%)

Phase Distribution

Ph not_applicable

Ph phase_2

18%

Ph early_phase_1

Ph phase_1

16%

Ph phase_3

Ph phase_4

48%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution44 total trials

Early Phase 1First-in-human

3(6.8%)

Phase 1Safety & dosage

7(15.9%)

Phase 2Efficacy & side effects

8(18.2%)

Phase 3Large-scale testing

4(9.1%)

Phase 4Post-market surveillance

21(47.7%)

N/ANon-phased studies

1(2.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.3%

28 of 31 finished

Non-Completion Rate

9.7%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(10)

Completed(28)

Terminated(3)

Other(3)

Detailed Status

Completed28

Recruiting9

unknown3

Terminated2

Not yet recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 13 (6.8%)

Phase 17 (15.9%)

Phase 28 (18.2%)

Phase 34 (9.1%)

Phase 421 (47.7%)

N/A1 (2.3%)

Trials by Status

not_yet_recruiting12%

completed2864%

terminated25%

recruiting920%

unknown37%

withdrawn12%

Recent Activity

9 active trials

Showing 5 of 44

recruitingphase_1

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

NCT06655883

View all 44 trials

Clinical Trials (44)

Showing 20 of 44 trialsScroll for more

NCT06484075Phase 1

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Recruiting

NCT05593653Phase 4

Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia

Completed

NCT06788522Phase 4

The Effects of Orexin Antagonism on Fear Extinction in PTSD

Not Yet Recruiting

NCT05546554Phase 2

Trial of Suvorexant for Sleep in Children With Autism

Recruiting

NCT06655883Phase 3

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

Recruiting

NCT06584942Phase 4

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

Recruiting

NCT06326684Early Phase 1

Suvorexant and Alcohol

Recruiting

NCT04287062Phase 2

Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

Completed

NCT05656534Early Phase 1

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

Completed

NCT04014387Phase 4

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

Completed

NCT05145764Phase 2

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

Recruiting

NCT06679062Phase 2

Suvorexant for Treatment of AUD and PTSD

Recruiting

NCT03642028Phase 4

Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress

Recruiting

NCT06834386Phase 4

Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients

Withdrawn

NCT05106153Phase 1

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Completed

NCT03110315Phase 4

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

Completed

NCT04571944Phase 3

Efficacy and Safety of Suvorexant (MK-4305) for Reducing Incidence of Delirium in Japanese Participants at High Risk of Delirium (MK-4305-085)

Completed

NCT04262193Phase 2

Dual-Orexin Antagonism As a Mechanism for Improving Sleep and Drug Abstinence in Opioid Use Disorder

Terminated

NCT02729714Phase 4

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

Completed

NCT03818581Phase 4

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 44